Compare Gilead Sciences, Inc. (GILD) vs Howmet Aerospace Inc (HWM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Howmet Aerospace Inc — how do they compare? Gilead Sciences, Inc. trades at $135.48 (market cap $163.51B), while Howmet Aerospace Inc trades at $270.1 (market cap $111.73B). The key difference: Gilead Sciences, Inc. is the larger of the two by market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | HWM | |
|---|---|---|
Market Cap | $163.51B | $111.73B |
Sector | Health | Industrials |
52-Week High | $155.80 | $283.23 |
52-Week Low | $108.22 | $171.00 |
Enterprise Value | $178.05B | $113.98B |
Dividend Yield | 2.49% | 0.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Howmet Aerospace (HWM) trades at $268.89, down 2.85% on the day but maintains strong bullish technical momentum with consistent earnings beats. The company reported robust Q1 2026 EPS of $1.22, exceeding expectations, driven by commercial aerospace demand. Valuation ratios remain elevated with a P/E of 64.79, reflecting growth premiums. Analyst consensus is overwhelmingly positive with 84% buy ratings and a $317.63 price target, indicating 18% upside potential from current levels.
Outlook remains favorable with aerospace cycle strength and defense contracts supporting revenue growth, though high valuation multiples pose sensitivity risks. Key risks include execution challenges in meeting production targets and macroeconomic pressures on travel demand. The stock's trajectory hinges on Q2 2026 results due August 6, 2026, where another beat could validate premium pricing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Howmet Aerospace Inc
Howmet Aerospace provides advanced engineered solutions for the aerospace and transportation industries. It specializes in jet engine components, aerospace fastening systems, and forged aluminum wheels.
Read more on HWM →
